Products
China Hansenula Polymorpha Recombinant Hepatitis B Immunization Vaccine Manufacturer, Supplier, Factory
Hansenula Polymorpha Recombinant Hepatitis B Immunization Vaccine is developed and manufactured by AIM Honesty Biopharmaceutical Co., Ltd., a professional vaccine manufacturer focusing on biological product research, development, and production. Based on the recombinant Hansenula polymorpha expression technology platform and patented adjuvant technology, the product provides a reliable immunization solution for organizations seeking stable hepatitis B prevention products.
For vaccine distributors, healthcare institutions, and medical procurement partners, selecting an appropriate hepatitis B vaccine requires consideration of multiple factors, including manufacturing experience, technical platform, quality control capability, and long-term supply reliability. AIM Honesty Biopharmaceutical Co., Ltd. provides vaccine products supported by established production experience and continuous biological technology development.
The RECVAX® series independently developed by AIM Honesty Biopharmaceutical Co., Ltd. adopts the first domestic and internationally leading recombinant Hansenula polymorpha expression technology platform combined with patented adjuvant technology. The product has been available for 20 years, covering 31 provinces, cities, and autonomous regions in China, with total market usage of nearly 500 million doses.
Hepatitis B Immunization Needs
Hepatitis B prevention requires continuous immunization strategies, especially for populations with higher exposure risks. Vaccination plays an important role in helping individuals develop immune protection against hepatitis B virus infection and supporting public health prevention programs.
The product developed by AIM Honesty Biopharmaceutical Co., Ltd. is designed for individuals susceptible to hepatitis B, providing healthcare organizations with an established vaccine option based on recombinant yeast expression technology.
Common application groups include:
1. Newborns, particularly those whose mothers are HBsAg and HBeAg positive.
2. Healthcare workers and laboratory personnel working in medical environments with potential blood exposure risks.
Expression Technology
Recombinant Hansenula Platform
The production technology is one of the key factors considered during vaccine selection. Hansenula polymorpha recombinant expression technology provides an advanced manufacturing approach for hepatitis B vaccine development, supporting controlled production processes and consistent product characteristics.
The Hansenula Polymorpha Recombinant Hepatitis B Immunization Vaccine uses the recombinant Hansenula polymorpha expression technology platform developed by AIM Honesty Biopharmaceutical Co., Ltd. This technology route is combined with professional manufacturing processes to support product quality and application performance.
Patented Adjuvant System
RECVAX® applies patented adjuvant technology based on in situ adsorption technology. After administration, this technology creates an "antigen bank" in the body, allowing continuous antigen release and extending antigen action time.
This mechanism helps enhance immune response stimulation and improve immunogenicity, providing technical support for long-term hepatitis B immunization needs.
Immune Protection Value
When healthcare organizations evaluate vaccine products, immune response performance and practical application experience are important considerations. A product with long-term market application can provide additional reference for procurement decisions.
A study led by Academician Li Lanjuan evaluated booster immunization among children aged 5 to 15 years using four different hepatitis B vaccines. After a 0-1-6-month booster series with 10 μg RECVAX® (Hansenula-yeast) vaccine, the anti-HBs seropositive rates at 1, 5, and 8 years after booster immunization reached 83.4%, which was the highest among the evaluated vaccines.
This research provides valuable information regarding the immune response characteristics of the Hansenula yeast vaccine technology route and supports understanding of its long-term immunization performance.
Product Development Background
AIM Honesty Biopharmaceutical Co., Ltd. focuses on vaccine innovation and biological product manufacturing. Through continuous investment in technology development and production capability improvement, the company has established experience in hepatitis B vaccine research and commercialization.
The RECVAX® series represents the company's focus on developing reliable hepatitis B prevention solutions by combining recombinant technology, manufacturing expertise, and application experience.
Product Specification
Product quality evaluation is an important part of vaccine procurement decisions. AIM Honesty Biopharmaceutical Co., Ltd. follows strict pharmacopeia standards during manufacturing, focusing on key quality indicators to support product consistency and safety management.
The following table presents the comparison of important quality-related items among different production systems.
| Pharmacopoeia Item | Endotoxin content | Free formaldehyde | Thiocyanate | Residual amount of antibiotics | Residual amount of bovine serum albumin |
| Hansenula polymorpha | Less than 5 EU/ml | Less than 15 µg/ml | Not applicable | Not applicable | Not applicable |
| Saccharomyces cerevisiae | Less than 5 EU/ml | Less than 20 µg/ml | Should be less than 1 µg/ml | Not applicable | Not applicable |
| CHO cells | Less than 10 EU/ml | Less than 50 µg/ml | Not applicable | No more than 50 ng/dose | No more than 50 ng/dose |
Technology Comparison
Different expression systems have different characteristics in production processes and product performance. Understanding these differences helps healthcare organizations and professional buyers evaluate suitable vaccine solutions according to their application requirements.
| Process | Hansenula Yeast | Saccharomyces Yeast | CHO Cell |
| Process Description | Most advanced process | First generation yeast expression system | Most dated process |
| Tumorigenic Risk? | No | No | Yes |
| Antibiotic Added? | No | No | Yes |
| Bovine Serum Albumin Added? | No | No | Yes |
| Animal Pathogen Risk? | No | No | Yes |
| Thiocyanate Added? | No | Yes | No |
| Immunogenicity | High | Higher | Not much (general double dose vs. yeast shows poor response) |
| Vaccine Purity | Highest | Higher | More additives, lower purity |
| Potential Benefit | Strongest cellular immunity induction | Second strongest cellular immunity induction | Weakest cellular immunity induction |
| Representative Product Statement | 10 µg applicable to all populations | 10 µg applicable only to children | 10 µg immunogenicity poor, almost discontinued |
Application Fields
The selection of a Hansenula Polymorpha Recombinant Hepatitis B Immunization Vaccine should consider the actual needs of different application environments. Hospitals, healthcare organizations, and medical distributors usually evaluate product technology, supply stability, and long-term cooperation capability together.
Newborn Immunization Programs
Newborn protection is one of the important application areas for hepatitis B vaccination. Early immunization can help establish immune protection during infancy, especially for newborns with increased infection exposure risks.
For medical institutions responsible for vaccination programs, a vaccine supplier with mature production experience can provide additional support for stable product supply and technical communication.
Healthcare Personnel Protection
Healthcare workers and laboratory personnel may encounter occupational exposure risks due to contact with blood or medical samples. Appropriate vaccination solutions are an important part of occupational health management.
Organizations selecting vaccine products often consider manufacturing background, quality management systems, and product consistency when establishing long-term procurement cooperation.
Manufacturing Strength
Professional production capability is an important foundation for biological product quality. AIM Honesty Biopharmaceutical Co., Ltd. has established modern production workshops and professional manufacturing systems to support vaccine production requirements.
The company's production environment, technical teams, and manufacturing processes work together to maintain product quality control throughout different production stages.
Quality Management
Vaccine manufacturing requires continuous attention to process control and product evaluation. AIM Honesty Biopharmaceutical Co., Ltd. focuses on maintaining reliable manufacturing procedures and quality management practices.
Important quality evaluation areas include:
1. Production process control: maintaining consistency during vaccine manufacturing procedures.
2. Quality indicator monitoring: evaluating key parameters related to product performance and manufacturing requirements.
3. Technical process management: applying established recombinant technology and professional production experience.
Company Experience
AIM Honesty Biopharmaceutical Co., Ltd. has accumulated professional experience in hepatitis B vaccine research, development, and manufacturing. The company focuses on biological product innovation and provides vaccine solutions supported by long-term technology development and production experience.
The RECVAX® series has been available on the market for 20 years. According to the provided company information, the product has covered 31 provinces, cities, and autonomous regions in China, with total market usage reaching nearly 500 million doses.
This long-term application experience demonstrates the company's continuous focus on hepatitis B prevention and provides valuable reference for healthcare organizations and professional procurement partners evaluating supplier capability.
Supply Cooperation
For international healthcare partners, selecting a vaccine supplier involves evaluating more than product specifications. Stable communication, professional technical support, and reliable manufacturing capability are also important factors during cooperation.
AIM Honesty Biopharmaceutical Co., Ltd. provides professional cooperation support based on its experience in vaccine development and production. The company focuses on maintaining clear product information, technical communication, and long-term cooperation with healthcare partners.
For hospitals, medical distributors, and healthcare organizations, working with an experienced manufacturer can help improve confidence during product evaluation and procurement processes.
Frequently Asked Questions
Q: What is the main application purpose of this vaccine product?
A: This Hansenula Polymorpha Recombinant Hepatitis B Immunization Vaccine is designed for hepatitis B immunization needs and is suitable for individuals susceptible to hepatitis B infection. According to the provided product information, important application groups include newborns and healthcare workers who may have exposure risks.
Q: Which technology platform is used during production?
A: The product is manufactured using recombinant Hansenula polymorpha expression technology. AIM Honesty Biopharmaceutical Co., Ltd. developed the RECVAX® series based on a recombinant Hansenula polymorpha expression technology platform combined with patented adjuvant technology.
Q: What is the advantage of using a recombinant yeast expression system?
A: Recombinant yeast expression technology provides an advanced production approach for vaccine development. According to the provided technical comparison, the Hansenula polymorpha system shows advantages in production characteristics, purity-related indicators, and potential immune response performance compared with other listed technology routes.
Q: How does the patented adjuvant technology work?
A: The patented adjuvant technology applies in situ adsorption technology to form an antigen bank after administration. This helps extend antigen action time and supports immune response stimulation.
Q: How much market application experience does AIM Honesty Biopharmaceutical Co., Ltd. have?
A: The RECVAX® series has been available on the market for 20 years. The product has been used in 31 provinces, cities, and autonomous regions in China, with total market usage of nearly 500 million doses according to the provided company information.
Q: What factors should buyers consider when selecting a vaccine manufacturer?
A: Professional buyers usually evaluate several aspects, including manufacturing experience, technology platform, product quality management, supply capability, and technical communication support. These factors help organizations establish reliable long-term cooperation.
Q: What quality controls are considered during manufacturing?
A: Quality management includes monitoring important product-related indicators such as endotoxin content, free formaldehyde level, residual substances, and other pharmacopeia-related requirements to support product consistency.
Q: Does AIM Honesty Biopharmaceutical Co., Ltd. support professional procurement cooperation?
A: AIM Honesty Biopharmaceutical Co., Ltd. focuses on biological product manufacturing and provides professional communication support for healthcare organizations, distributors, and other partners requiring vaccine products.
Conclusion
Choosing a suitable hepatitis B vaccine requires consideration of technology development, manufacturing experience, product quality management, and supplier reliability. AIM Honesty Biopharmaceutical Co., Ltd. combines recombinant Hansenula polymorpha expression technology with patented adjuvant technology to provide a vaccine solution supported by established production experience.
With 20 years of market application experience and nearly 500 million doses used, the RECVAX® series reflects the company's continuous commitment to hepatitis B prevention and biological product development. For healthcare institutions and professional procurement partners, the Hansenula Polymorpha Recombinant Hepatitis B Immunization Vaccine provides a reliable choice based on proven technology and manufacturing expertise.
Related Products
Hot Products
W-Type Meningitis Vaccine
If you need a reliable supplier of W-Type Meningitis Vaccine, consider AIM Persistence Biopharmaceutical Co., Ltd. We are a Chinese company that develops vaccines using advanced domestic and international technologies. Our Xin'er Cong® series is an upgraded vaccine developed to address the threat of multiple serotypes of meningococcal meningitis, including W-type. It effectively prevents infection from four serotypes of meningococcal bacteria: A, C, Y, and W135 (W-type).
Intramuscular Rabies Vaccine
AIM Honor, a reliable manufacturer of rabies vaccines, offers both conventional and serum-free versions, both of which are Intramuscular Rabies Vaccines. The conventional version boasts a mature manufacturing process and a 100% batch release qualification rate over 17 years, while the serum-free version is an innovative formulation adapted to diverse scenarios. Both offer highly effective immunity.
Hepatitis A Vaccine
AIM Action Biopharmaceutical Co., Ltd. (a wholly-owned subsidiary of AIM Vaccine Co., Ltd.) is a manufacturer and supplier of Adult Hepatitis A Vaccine, offering a precise antigen content of 640 EU/ml. The vaccine utilizes a safe human diploid cell culture and inactivation process, providing a highly effective and rapid antibody response.
Immunization Against Hepatitis A
Immunization against Hepatitis A is the most effective and economical means of preventing hepatitis A. AIM Action Biopharmaceutical Co., Ltd. is a reliable manufacturer of inactivated hepatitis A vaccines, utilizing internationally advanced cell culture and inactivation processes, and its products are recommended for inclusion in national non-immunization programs.
Adult Hepatitis B Vaccine
AIM Honesty Biopharmaceutical Co., Ltd., a part of the AIM Group, is a professional manufacturer and supplier of adult hepatitis B vaccines, possessing strong R&D and supply capabilities. Our RECVAX® hepatitis B vaccine protects adults, providing protection for up to 20-30 years, with proven efficacy and safety.
Freeze-Dried Rabies Vaccine
AIM Honor (Ningbo) Biopharmaceutical Co., Ltd. is a manufacturer and supplier of freeze-dried rabies vaccine. Our product is preservative-free, has a long shelf life of 36 months for easy storage and transportation, and strictly adheres to standardized immunization procedures. It is suitable for pre- and post-exposure prophylaxis in all populations. We support customized procurement and cross-border supply, making us a trusted choice for global rabies control. We welcome inquiries and collaborations!
- Related Blog
- Reviews
